What caused the NMRD stock spike today?

The intraday spike in NMRD stock came from renewed interest in the sugarBEAT product and fresh coverage on MarketBeat. Low float and light volume (**2,201** shares) amplified price moves. Expect news or earnings as likely further catalysts.

Is NMRD stock a buy after the intraday rise?

NMRD stock shows high percentage upside potential in forecasts but carries major liquidity and fundamental risks. Meyka AI grades NMRD **61.26** (Grade B, HOLD). Investors should wait for clearer revenue or clinical progress before buying.

When is the next NMRD earnings report?

Nemaura has an earnings announcement scheduled for **2026-02-27**. That report is a key near-term catalyst that could shift NMRD stock sentiment depending on revenue and guidance.

What does the Meyka AI forecast say about NMRD stock?

Meyka AI's forecast model projects **$0.000543** in one year and **$0.000661** in three years. Against the current **$0.0001**, implied upside is **443.16%** at one year and **561.05%** at three years. Forecasts are projections, not guarantees.

US Stocks

NMRD stock jumps to $0.0001 on 02 Feb 2026: intraday top gainer with upside signals

ByDanny Kontos February 2, 2026

NMRD stock is trading at $0.0001 on NASDAQ in the United States after an intraday rise from $0.000001 to $0.0001, a 9900.00% move that puts the micro-cap among today’s top gainers. Volume is light at 2,201 shares versus an average of 3,472, keeping liquidity a key issue for traders. We examine what drove the spike, the company’s fundamentals, technical signals, and the model forecast that frames potential upside and risks for investors.